SCHEMBL4960702

SCHEMBL4960702

N#Cc1cnc2c(-c3ccoc3)cc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1

nearest known ligand 0.77

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAP3K8 P41279 20/20 0.77
MAPK14 Q16539 2/20 0.61
MAPK13 O15264 1/20 0.61
EIF2AK2 P19525 1/20 0.61
MAPK12 P53778 1/20 0.61
MAPK11 Q15759 1/20 0.61
EGFR P00533 4/20 0.55
SRC P12931 2/20 0.55
PRKACA P17612 2/20 0.55
PRKACG P22612 2/20 0.55
PRKACB P22694 2/20 0.55
CYP3A4 P08684 2/20 0.55
MAPKAPK2 P49137 2/20 0.55
IKBKB O14920 1/20 0.55
MMP3 P08254 1/20 0.55
PRKCA P17252 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4960344 0.88 MAP3K8 (1.00) MAP3K8MAPK14MAPK13EIF2AK2MAPK12
SCHEMBL4960399 0.84 MAP3K8 (0.87) MAP3K8MAPK14MAPK13EIF2AK2MAPK12
SCHEMBL4961579 0.83 MAP3K8 (0.84) MAP3K8MAPK14MAPK13EIF2AK2MAPK12
SCHEMBL4960411 0.82 MAP3K8 (0.83) MAP3K8MAPK14MAPK13EIF2AK2MAPK12
SCHEMBL4960407 0.82 MAP3K8 (0.83) MAP3K8MAPK14MAPK13EIF2AK2MAPK12
SCHEMBL4963677 0.82 MAP3K8 (0.83) MAP3K8MAPK14MAPK13EIF2AK2MAPK12
SCHEMBL4960699 0.82 MAP3K8 (0.61) MAP3K8MAPK14MAPK13EIF2AK2MAPK12
SCHEMBL4963305 0.81 MAP3K8 (0.83) MAP3K8MAPK14MAPK13EIF2AK2MAPK12
SCHEMBL4962602 0.80 MAP3K8 (0.82) MAP3K8MAPK14EGFRSRCPRKACA
SCHEMBL4963165 0.80 MAP3K8 (0.71) MAP3K8MAPK14EGFRSRCCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101223143-A 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same WYETH CORP (US) 2008-07-16 CN disclosed
EP-1888529-A2 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME Wyeth (US) 2008-02-20 EP disclosed
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-11-23 US disclosed
WO-2006124692-A2 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CSNK1A1L, CDKL1 MAP3K8 84/4885MAPK14 565/4885MAPK13 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.